JP2008534496A - CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 - Google Patents
CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 Download PDFInfo
- Publication number
- JP2008534496A JP2008534496A JP2008502944A JP2008502944A JP2008534496A JP 2008534496 A JP2008534496 A JP 2008534496A JP 2008502944 A JP2008502944 A JP 2008502944A JP 2008502944 A JP2008502944 A JP 2008502944A JP 2008534496 A JP2008534496 A JP 2008534496A
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- pyrido
- alkyl
- indole
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title description 6
- ZRGIHRLCJVIUNZ-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-pyrido[4,3-b]indole Chemical class N1=C2C=CC=CC2=C2C1CCNC2 ZRGIHRLCJVIUNZ-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 208
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 208000002193 Pain Diseases 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 230000036407 pain Effects 0.000 claims abstract description 16
- -1 methoxy, ethoxy Chemical group 0.000 claims description 693
- 125000000217 alkyl group Chemical group 0.000 claims description 304
- 239000000203 mixture Substances 0.000 claims description 239
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 233
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 78
- 238000004519 manufacturing process Methods 0.000 claims description 77
- 229910052757 nitrogen Inorganic materials 0.000 claims description 59
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 38
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 37
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 15
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 6
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 6
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 5
- ORNLNZUOLVBBSU-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(2-piperidin-4-yl-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C2CCNCC2)C3=C1 ORNLNZUOLVBBSU-UHFFFAOYSA-N 0.000 claims description 4
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 4
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 claims description 4
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- BZYPOSYJBZSSOY-UHFFFAOYSA-N (2-cyclopentyl-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 BZYPOSYJBZSSOY-UHFFFAOYSA-N 0.000 claims description 3
- UCJRHXRUVGNGBQ-UHFFFAOYSA-N (2-cyclopentyl-5-imidazol-1-ylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCCC2)S(=O)(=O)N2C=NC=C2)C3=C1 UCJRHXRUVGNGBQ-UHFFFAOYSA-N 0.000 claims description 3
- GENVWGFKMWRWGX-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(2-propan-2-yl-1,3,4,5-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1=C2C=3CN(C(C)C)CCC=3NC2=CC=C1C(=O)N1CCC(C)CC1 GENVWGFKMWRWGX-UHFFFAOYSA-N 0.000 claims description 3
- LEYYJOBTMJQHCX-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 LEYYJOBTMJQHCX-UHFFFAOYSA-N 0.000 claims description 3
- WQKRVODUOZJARR-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxolan-3-yl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCN(C4COCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 WQKRVODUOZJARR-UHFFFAOYSA-N 0.000 claims description 3
- KGDCOHTYENZVQV-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-propyl-2-(3,3,3-trifluoropropyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(CCC)C=3CCN(CCC(F)(F)F)CC=3C2=CC=1C(=O)N1CCC(C)CC1 KGDCOHTYENZVQV-UHFFFAOYSA-N 0.000 claims description 3
- YVSNOWBNDCFRGB-UHFFFAOYSA-N 2-[2-cyclopentyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]acetic acid Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC(O)=O)C2=C3CN(CC2)C2CCCC2)C3=C1 YVSNOWBNDCFRGB-UHFFFAOYSA-N 0.000 claims description 3
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- BDSOSZNUEDOYNB-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-[(4-ethoxyphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C(C2)=C1CCN2CC1CC1 BDSOSZNUEDOYNB-UHFFFAOYSA-N 0.000 claims description 3
- MVIUOIRYEBIYLG-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-methylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC4CC4)CC2)S(C)(=O)=O)C3=C1 MVIUOIRYEBIYLG-UHFFFAOYSA-N 0.000 claims description 3
- ATFPKCCWKBNASV-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC4CC4)CC2)C3=C1 ATFPKCCWKBNASV-UHFFFAOYSA-N 0.000 claims description 3
- KPIWYZKCJJXJPN-UHFFFAOYSA-N [2-cyclobutyl-5-(1-methylimidazol-4-yl)sulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCC2)S(=O)(=O)C=2N=CN(C)C=2)C3=C1 KPIWYZKCJJXJPN-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims description 3
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims description 3
- NZLFMVRXBYBIPI-UHFFFAOYSA-N methyl 2-[2-cyclopentyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]acetate Chemical compound C=1C=C2N(CC(=O)OC)C=3CCN(C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 NZLFMVRXBYBIPI-UHFFFAOYSA-N 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- XSDISIAXSICJFF-UHFFFAOYSA-N n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-carboxamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C(=O)N(C)C)C2=C3CN(CC2)C2CCOCC2)C3=C1 XSDISIAXSICJFF-UHFFFAOYSA-N 0.000 claims description 3
- MKXCSIZMPVFGDY-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)benzenesulfonamide Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NS(=O)(=O)C1=CC=CC=C1 MKXCSIZMPVFGDY-UHFFFAOYSA-N 0.000 claims description 3
- JNRJINSDQQDNSH-UHFFFAOYSA-N n-ethyl-8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C=1C=C2N(S(=O)(=O)NCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 JNRJINSDQQDNSH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 3
- 125000004673 propylcarbonyl group Chemical group 0.000 claims description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- HEFJJXPUDGTDOQ-UHFFFAOYSA-N (2-cyclobutyl-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-[4-(hydroxymethyl)piperidin-1-yl]methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCC4)CC=3C2=CC=1C(=O)N1CCC(CO)CC1 HEFJJXPUDGTDOQ-UHFFFAOYSA-N 0.000 claims description 2
- NQVZYJPSQLRLKC-UHFFFAOYSA-N (2-cyclopentyl-1,3,4,5-tetrahydropyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(NC2=C3CN(CC2)C2CCCC2)C3=C1 NQVZYJPSQLRLKC-UHFFFAOYSA-N 0.000 claims description 2
- TVKWKGUKDRRICW-UHFFFAOYSA-N (2-cyclopentyl-5-ethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CC)C=3CCN(C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 TVKWKGUKDRRICW-UHFFFAOYSA-N 0.000 claims description 2
- XDAZKNRNAJTBKN-UHFFFAOYSA-N (2-cyclopentyl-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4,4-difluoropiperidin-1-yl)methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(F)(F)CC1 XDAZKNRNAJTBKN-UHFFFAOYSA-N 0.000 claims description 2
- AMHQJYVBDKPZSA-UHFFFAOYSA-N (2-cyclopentyl-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C)C2=C3CN(CC2)C2CCCC2)C3=C1 AMHQJYVBDKPZSA-UHFFFAOYSA-N 0.000 claims description 2
- MPUHRMVUUZAIMH-UHFFFAOYSA-N (2-cyclopentyl-5-methylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCCC2)S(C)(=O)=O)C3=C1 MPUHRMVUUZAIMH-UHFFFAOYSA-N 0.000 claims description 2
- PUDOYHVREJTDBQ-UHFFFAOYSA-N (2-cyclopentyl-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 PUDOYHVREJTDBQ-UHFFFAOYSA-N 0.000 claims description 2
- HWEKJGHXKXPACQ-UHFFFAOYSA-N (4,4-difluoropiperidin-1-yl)-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(F)(F)CC1 HWEKJGHXKXPACQ-UHFFFAOYSA-N 0.000 claims description 2
- NSGOQJGVYWSOGC-UHFFFAOYSA-N (4,4-difluoropiperidin-1-yl)-[5-methyl-2-(oxolan-3-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4COCC4)CC=3C2=CC=1C(=O)N1CCC(F)(F)CC1 NSGOQJGVYWSOGC-UHFFFAOYSA-N 0.000 claims description 2
- QDCQXJDWHGCBHR-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(2-propan-2-yl-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 QDCQXJDWHGCBHR-UHFFFAOYSA-N 0.000 claims description 2
- QEZXZSYRSPZABJ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-pentyl-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(CCCCC)C=3CCN(C(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 QEZXZSYRSPZABJ-UHFFFAOYSA-N 0.000 claims description 2
- WNCDFELRTFXLNY-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-yl)-5-(pyridin-2-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2N=CC=CC=2)C2=C3CN(CC2)C2CCOCC2)C3=C1 WNCDFELRTFXLNY-UHFFFAOYSA-N 0.000 claims description 2
- JLYURUXNAAKJAD-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-yl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C2CCOCC2)C3=C1 JLYURUXNAAKJAD-UHFFFAOYSA-N 0.000 claims description 2
- XKSUFUUEUFNEJX-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-yl)-5-propan-2-ylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(S(=O)(=O)C(C)C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 XKSUFUUEUFNEJX-UHFFFAOYSA-N 0.000 claims description 2
- LCLHWAFOYICJIC-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-yl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 LCLHWAFOYICJIC-UHFFFAOYSA-N 0.000 claims description 2
- KJGMABJBFGRVGD-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxan-4-ylmethyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC4CCOCC4)CC2)C3=C1 KJGMABJBFGRVGD-UHFFFAOYSA-N 0.000 claims description 2
- ZZNUMTXHWKDNJV-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxolan-3-yl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C2COCC2)C3=C1 ZZNUMTXHWKDNJV-UHFFFAOYSA-N 0.000 claims description 2
- HSPRONAVKPLBTP-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[2-(oxolan-3-ylmethyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCC)C=2CCN1CC1CCOC1 HSPRONAVKPLBTP-UHFFFAOYSA-N 0.000 claims description 2
- MNJQTTGWERHCJH-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-(4-nitrophenyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)C=2C=CC(=CC=2)[N+]([O-])=O)C3=C1 MNJQTTGWERHCJH-UHFFFAOYSA-N 0.000 claims description 2
- GPBJSKKOWXKACF-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-(morpholine-4-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C(=O)N2CCOCC2)C2=C3CN(CC2)C2CCOCC2)C3=C1 GPBJSKKOWXKACF-UHFFFAOYSA-N 0.000 claims description 2
- XUQWJBJECUXYDA-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-methylsulfonyl-2-(3,3,3-trifluoropropyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CCC(F)(F)F)CC2)S(C)(=O)=O)C3=C1 XUQWJBJECUXYDA-UHFFFAOYSA-N 0.000 claims description 2
- GZBNSNLOUUIGBF-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-methylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(C)(=O)=O)C3=C1 GZBNSNLOUUIGBF-UHFFFAOYSA-N 0.000 claims description 2
- KKQXADSDISBOJZ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-propylsulfonyl-2-(3,3,3-trifluoropropyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCN(CCC(F)(F)F)CC=3C2=CC=1C(=O)N1CCC(C)CC1 KKQXADSDISBOJZ-UHFFFAOYSA-N 0.000 claims description 2
- XXTCWHWLUCBCRL-UHFFFAOYSA-N (5-benzyl-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1N(C(C)C)CCC2=C1C1=CC(C(=O)N3CCC(C)CC3)=CC=C1N2CC1=CC=CC=C1 XXTCWHWLUCBCRL-UHFFFAOYSA-N 0.000 claims description 2
- ZBPSHEAJVGPDFK-UHFFFAOYSA-N 1-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)-3-ethylurea Chemical compound C1C2C3=CC(NC(=O)NCC)=CC=C3N(CCC)C2CCN1C1CCCC1 ZBPSHEAJVGPDFK-UHFFFAOYSA-N 0.000 claims description 2
- QHQBQJWYZPQSBA-UHFFFAOYSA-N 1-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)-3-phenylurea Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NC(=O)NC1=CC=CC=C1 QHQBQJWYZPQSBA-UHFFFAOYSA-N 0.000 claims description 2
- JWOQQUODEBPMME-UHFFFAOYSA-N 1-[2-cyclobutyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]butan-1-one Chemical compound C=1C=C2N(C(=O)CCC)C=3CCN(C4CCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 JWOQQUODEBPMME-UHFFFAOYSA-N 0.000 claims description 2
- CBRCWAVGAWOTCB-UHFFFAOYSA-N 1-cyclopentyl-3-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)urea Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NC(=O)NC1CCCC1 CBRCWAVGAWOTCB-UHFFFAOYSA-N 0.000 claims description 2
- UOSMIOCXTOYXOK-UHFFFAOYSA-N 2,2-difluoro-1-[8-(4-methylpiperidine-1-carbonyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]propan-1-one Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C(=O)C(C)(F)F)C3=C1 UOSMIOCXTOYXOK-UHFFFAOYSA-N 0.000 claims description 2
- WOZOUJVEQDNDCB-UHFFFAOYSA-N 2,2-difluoro-1-[8-(4-methylpiperidine-1-carbonyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]propan-1-one Chemical compound C=1C=C2N(CCC)C=3CCN(C(=O)C(C)(F)F)CC=3C2=CC=1C(=O)N1CCC(C)CC1 WOZOUJVEQDNDCB-UHFFFAOYSA-N 0.000 claims description 2
- XYVVKDQOILDYRL-UHFFFAOYSA-N 2-[2-cyclohexyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]-n,n-dimethylacetamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC(=O)N(C)C)C2=C3CN(CC2)C2CCCCC2)C3=C1 XYVVKDQOILDYRL-UHFFFAOYSA-N 0.000 claims description 2
- WYRUYTRZZMGZQQ-UHFFFAOYSA-N 2-[[8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]sulfonyl]benzoic acid Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)C=2C(=CC=CC=2)C(O)=O)C3=C1 WYRUYTRZZMGZQQ-UHFFFAOYSA-N 0.000 claims description 2
- LHRUBCPQJWSCDH-UHFFFAOYSA-N 2-cyclobutyl-n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-carboxamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C(=O)N(C)C)C2=C3CN(CC2)C2CCC2)C3=C1 LHRUBCPQJWSCDH-UHFFFAOYSA-N 0.000 claims description 2
- HBNFLNXIXRTYTC-UHFFFAOYSA-N 2-cyclopentyl-n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCCC2)S(=O)(=O)N(C)C)C3=C1 HBNFLNXIXRTYTC-UHFFFAOYSA-N 0.000 claims description 2
- RUQMQGIXVFXBGL-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-[2-(1-methylpiperidin-4-yl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1C=2C3=CC(C(=O)N4CC5=CC=CC=C5CC4)=CC=C3N(S(=O)(=O)CCC)C=2CCN1C1CCN(C)CC1 RUQMQGIXVFXBGL-UHFFFAOYSA-N 0.000 claims description 2
- BRXSGBLPIZRUMJ-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-[5-ethylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1C=2C3=CC(C(=O)N4CC5=CC=CC=C5CC4)=CC=C3N(S(=O)(=O)CC)C=2CCN1C1CCOCC1 BRXSGBLPIZRUMJ-UHFFFAOYSA-N 0.000 claims description 2
- KCSHFMUBPRUWTI-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-[5-ethylsulfonyl-2-(oxolan-2-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1C=2C3=CC(C(=O)N4CC5=CC=CC=C5CC4)=CC=C3N(S(=O)(=O)CC)C=2CCN1C1CCCO1 KCSHFMUBPRUWTI-UHFFFAOYSA-N 0.000 claims description 2
- SGTCHVSZVLIDTQ-UHFFFAOYSA-N 5-[[2-cyclopentyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]methyl]furan-2-carboxylic acid Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2OC(=CC=2)C(O)=O)C2=C3CN(CC2)C2CCCC2)C3=C1 SGTCHVSZVLIDTQ-UHFFFAOYSA-N 0.000 claims description 2
- DUZZCRXFDYPJFU-UHFFFAOYSA-N [2-(2,2-difluoroethyl)-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(CC(F)F)CC=3C2=CC=1C(=O)N1CCC(C)CC1 DUZZCRXFDYPJFU-UHFFFAOYSA-N 0.000 claims description 2
- MTEYZEUVPQGYAB-UHFFFAOYSA-N [2-(3,4-dihydro-2h-pyrrol-5-yl)-5-[(4-ethoxyphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C=1CCCN=1)C2 MTEYZEUVPQGYAB-UHFFFAOYSA-N 0.000 claims description 2
- RMUABMASIDBYLK-UHFFFAOYSA-N [2-(3,4-dihydro-2h-pyrrol-5-yl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCN(C=4CCCN=4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 RMUABMASIDBYLK-UHFFFAOYSA-N 0.000 claims description 2
- VAQRHCRTQRJWKH-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-(oxan-4-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CCOCC2)C2=C3CN(CC4CC4)CC2)C3=C1 VAQRHCRTQRJWKH-UHFFFAOYSA-N 0.000 claims description 2
- VJWLYZDNHBODEG-UHFFFAOYSA-N [2-cyclopentyl-5-(cyclopropylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CC2)C2=C3CN(CC2)C2CCCC2)C3=C1 VJWLYZDNHBODEG-UHFFFAOYSA-N 0.000 claims description 2
- BJJMFHZGOXUYKR-UHFFFAOYSA-N [2-cyclopentyl-5-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2N=C(C)SC=2)C2=C3CN(CC2)C2CCCC2)C3=C1 BJJMFHZGOXUYKR-UHFFFAOYSA-N 0.000 claims description 2
- SVKPGQVXHQUPDO-UHFFFAOYSA-N [2-cyclopentyl-5-[(4-methylsulfanylphenyl)methyl]-2-oxido-3,4-dihydro-1h-pyrido[4,3-b]indol-2-ium-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(SC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CC[N+]([O-])(C1CCCC1)C2 SVKPGQVXHQUPDO-UHFFFAOYSA-N 0.000 claims description 2
- ZFURERTXCIPRLH-UHFFFAOYSA-N [2-cyclopentyl-5-[(4-methylsulfanylphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(SC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C1CCCC1)C2 ZFURERTXCIPRLH-UHFFFAOYSA-N 0.000 claims description 2
- HTNYVWHHNPQKRS-UHFFFAOYSA-N [2-cyclopentyl-5-[(4-methylsulfonylphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2C=CC(=CC=2)S(C)(=O)=O)C2=C3CN(CC2)C2CCCC2)C3=C1 HTNYVWHHNPQKRS-UHFFFAOYSA-N 0.000 claims description 2
- YNKLHYHLUVNZIK-UHFFFAOYSA-N [2-cyclopentyl-5-[(5-methyl-1,2-oxazol-4-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2=C(ON=C2)C)C2=C3CN(CC2)C2CCCC2)C3=C1 YNKLHYHLUVNZIK-UHFFFAOYSA-N 0.000 claims description 2
- LTJVIJHEUMWHNQ-UHFFFAOYSA-N [5-(1-methylimidazol-4-yl)sulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)C=2N=CN(C)C=2)C3=C1 LTJVIJHEUMWHNQ-UHFFFAOYSA-N 0.000 claims description 2
- QCOQITYVWOXUCU-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCOC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 QCOQITYVWOXUCU-UHFFFAOYSA-N 0.000 claims description 2
- DVKUHMWHFDIMJO-UHFFFAOYSA-N [5-(benzenesulfonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)C=2C=CC=CC=2)C3=C1 DVKUHMWHFDIMJO-UHFFFAOYSA-N 0.000 claims description 2
- FSVUUMALPPRGGI-UHFFFAOYSA-N [5-(cyclobutylmethyl)-2-cyclopentyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CCC2)C2=C3CN(CC2)C2CCCC2)C3=C1 FSVUUMALPPRGGI-UHFFFAOYSA-N 0.000 claims description 2
- CQBGJAUHLXXWJN-UHFFFAOYSA-N [5-[(2,6-difluorophenyl)methyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C1=CC=C(N(CC=2C(=CC=CC=2F)F)C2=C3CN(CC2)C(C)C)C3=C1 CQBGJAUHLXXWJN-UHFFFAOYSA-N 0.000 claims description 2
- GATPKMYOJPZDNL-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-(2-methylpropyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(CC(C)C)C2 GATPKMYOJPZDNL-UHFFFAOYSA-N 0.000 claims description 2
- ZZPRUFQKSMSCLW-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C1CCOCC1)C2 ZZPRUFQKSMSCLW-UHFFFAOYSA-N 0.000 claims description 2
- AKLSVTVKVPYNHV-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(CC3)OC)C=C2C2=C1CCN(C(C)C)C2 AKLSVTVKVPYNHV-UHFFFAOYSA-N 0.000 claims description 2
- MXSFGYZJQXJQCC-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1N(CCC)CCC2=C1C1=CC(C(=O)N3CCC(C)CC3)=CC=C1N2CC1=CC=C(OCC)C=C1 MXSFGYZJQXJQCC-UHFFFAOYSA-N 0.000 claims description 2
- JCRXYOGVNHZBJI-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-pyrimidin-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C=1N=CC=CN=1)C2 JCRXYOGVNHZBJI-UHFFFAOYSA-N 0.000 claims description 2
- LXSWSVZTCDAQKR-UHFFFAOYSA-N [5-[(4-methoxyphenyl)methyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C(C)C)C2 LXSWSVZTCDAQKR-UHFFFAOYSA-N 0.000 claims description 2
- XXAANGXTHDJWIZ-UHFFFAOYSA-N [5-[(5-methyl-1,2-oxazol-4-yl)sulfonyl]-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)C2=C(ON=C2)C)C3=C1 XXAANGXTHDJWIZ-UHFFFAOYSA-N 0.000 claims description 2
- MNIPFNGXJLSGHK-UHFFFAOYSA-N [5-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C1=CC=C(N(CC=2C(=CC=3OCOC=3C=2)Cl)C2=C3CN(CC2)C(C)C)C3=C1 MNIPFNGXJLSGHK-UHFFFAOYSA-N 0.000 claims description 2
- LWUVJNFMXIDOOI-UHFFFAOYSA-N [5-cyclopropylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)C2CC2)C3=C1 LWUVJNFMXIDOOI-UHFFFAOYSA-N 0.000 claims description 2
- NBPLAQPSYNGUKP-UHFFFAOYSA-N [5-ethyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 NBPLAQPSYNGUKP-UHFFFAOYSA-N 0.000 claims description 2
- KQAHDCSHFZPRLH-UHFFFAOYSA-N [5-ethylsulfonyl-2-(1-methylpiperidin-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCN(C)CC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 KQAHDCSHFZPRLH-UHFFFAOYSA-N 0.000 claims description 2
- YJQLRPARZZLPEZ-UHFFFAOYSA-N [5-ethylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(OC)CC1 YJQLRPARZZLPEZ-UHFFFAOYSA-N 0.000 claims description 2
- OINCQRGOMJVZHD-UHFFFAOYSA-N [5-ethylsulfonyl-2-(oxolan-3-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4COCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 OINCQRGOMJVZHD-UHFFFAOYSA-N 0.000 claims description 2
- KQPJRFXWAWUUTE-UHFFFAOYSA-N [5-imidazol-1-ylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)N2C=NC=C2)C3=C1 KQPJRFXWAWUUTE-UHFFFAOYSA-N 0.000 claims description 2
- GUDSPOSQRRZORN-UHFFFAOYSA-N cyclobutyl-[5-[(4-ethoxyphenyl)methyl]-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C(=O)C1CCC1)C2 GUDSPOSQRRZORN-UHFFFAOYSA-N 0.000 claims description 2
- TTXROTXBANFUIL-UHFFFAOYSA-N cyclobutyl-[8-(4-methylpiperidine-1-carbonyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C(=O)C4CCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 TTXROTXBANFUIL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims description 2
- KEQCRARZBQNJQJ-UHFFFAOYSA-N cyclopentyl-[8-(4-methylpiperidine-1-carbonyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C(=O)C2CCCC2)C3=C1 KEQCRARZBQNJQJ-UHFFFAOYSA-N 0.000 claims description 2
- KUKFQVOAHXOHNL-UHFFFAOYSA-N cyclopentyl-[8-(4-methylpiperidine-1-carbonyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C(=O)C4CCCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 KUKFQVOAHXOHNL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 2
- DWSGEHPLNSEZOT-UHFFFAOYSA-N methyl 5-[[2-cyclopentyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]methyl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C1CCCC1)C2 DWSGEHPLNSEZOT-UHFFFAOYSA-N 0.000 claims description 2
- MTTQUXMMKJLVQI-UHFFFAOYSA-N n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-2-(3,3,3-trifluoropropyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CCC(F)(F)F)CC2)S(=O)(=O)N(C)C)C3=C1 MTTQUXMMKJLVQI-UHFFFAOYSA-N 0.000 claims description 2
- IOBGWHNZXXNBCX-UHFFFAOYSA-N n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)S(=O)(=O)N(C)C)C3=C1 IOBGWHNZXXNBCX-UHFFFAOYSA-N 0.000 claims description 2
- JGAUXIRUFFBYAM-UHFFFAOYSA-N n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-2-(oxolan-3-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2COCC2)S(=O)(=O)N(C)C)C3=C1 JGAUXIRUFFBYAM-UHFFFAOYSA-N 0.000 claims description 2
- CTNUFTATIHKKSO-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)benzamide Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NC(=O)C1=CC=CC=C1 CTNUFTATIHKKSO-UHFFFAOYSA-N 0.000 claims description 2
- LMTALNKYSCWTHC-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)cyclopentanecarboxamide Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NC(=O)C1CCCC1 LMTALNKYSCWTHC-UHFFFAOYSA-N 0.000 claims description 2
- FUWDLDCAGSELMV-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)cyclopropanecarboxamide Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NC(=O)C1CC1 FUWDLDCAGSELMV-UHFFFAOYSA-N 0.000 claims description 2
- DGSIRHNFMHTWRR-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)ethanesulfonamide Chemical compound C1C2C3=CC(NS(=O)(=O)CC)=CC=C3N(CCC)C2CCN1C1CCCC1 DGSIRHNFMHTWRR-UHFFFAOYSA-N 0.000 claims description 2
- OHCNXSUCGCOZBE-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)propanamide Chemical compound C1C2C3=CC(NC(=O)CC)=CC=C3N(CCC)C2CCN1C1CCCC1 OHCNXSUCGCOZBE-UHFFFAOYSA-N 0.000 claims description 2
- CSVFPZZQZFQCBZ-UHFFFAOYSA-N n-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]cyclohexanecarboxamide Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCCCC1 CSVFPZZQZFQCBZ-UHFFFAOYSA-N 0.000 claims description 2
- TZVMLNBCHPIZID-UHFFFAOYSA-N n-[4-[8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]phenyl]acetamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCOCC2)C=2C=CC(NC(C)=O)=CC=2)C3=C1 TZVMLNBCHPIZID-UHFFFAOYSA-N 0.000 claims description 2
- FWADLSFMEAEECJ-UHFFFAOYSA-N n-[5-ethylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NS(=O)(=O)C1=CN(C)C=N1 FWADLSFMEAEECJ-UHFFFAOYSA-N 0.000 claims description 2
- NIYJRGMFSHSNMP-UHFFFAOYSA-N n-[5-ethylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]pyrrolidine-1-carboxamide Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)N1CCCC1 NIYJRGMFSHSNMP-UHFFFAOYSA-N 0.000 claims description 2
- VMPPJORJEAPMIC-UHFFFAOYSA-N n-[5-methylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]cyclopentanecarboxamide Chemical compound C=1C=C2N(S(=O)(=O)C)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCCC1 VMPPJORJEAPMIC-UHFFFAOYSA-N 0.000 claims description 2
- BAXKVCDKRUGYBB-UHFFFAOYSA-N (2-cyclobutyl-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-hydroxypiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCC4)CC=3C2=CC=1C(=O)N1CCC(O)CC1 BAXKVCDKRUGYBB-UHFFFAOYSA-N 0.000 claims 1
- UZZMNKDKHIEBRE-UHFFFAOYSA-N (2-cyclobutyl-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 UZZMNKDKHIEBRE-UHFFFAOYSA-N 0.000 claims 1
- CGCOYHXVKNETLI-UHFFFAOYSA-N (2-cyclobutyl-5-methylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCC2)S(C)(=O)=O)C3=C1 CGCOYHXVKNETLI-UHFFFAOYSA-N 0.000 claims 1
- AQBOFTWRMLZDBS-UHFFFAOYSA-N (4,4-dimethylpiperidin-1-yl)-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)(C)CC1 AQBOFTWRMLZDBS-UHFFFAOYSA-N 0.000 claims 1
- LFQBUARMCBNNME-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(O)CC1 LFQBUARMCBNNME-UHFFFAOYSA-N 0.000 claims 1
- XRNFCSLZGJJJPC-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-propyl-2-pyridin-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C=4N=CC=CC=4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 XRNFCSLZGJJJPC-UHFFFAOYSA-N 0.000 claims 1
- JGBJMAXYYWJANQ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-propyl-2-(2,3,4,5-tetrahydropyridin-6-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C=4CCCCN=4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 JGBJMAXYYWJANQ-UHFFFAOYSA-N 0.000 claims 1
- MSMSUUMPTDDUPS-UHFFFAOYSA-N (4-tert-butylpiperidin-1-yl)-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C(C)(C)C)CC1 MSMSUUMPTDDUPS-UHFFFAOYSA-N 0.000 claims 1
- BMHIBCNWAACRRU-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decan-8-yl-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N(CC1)CCC21OCCO2 BMHIBCNWAACRRU-UHFFFAOYSA-N 0.000 claims 1
- DORYOPLPKBBLFQ-UHFFFAOYSA-N 1-[8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]butan-1-one Chemical compound C=1C=C2N(C(=O)CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 DORYOPLPKBBLFQ-UHFFFAOYSA-N 0.000 claims 1
- FQGMRZAPDZONKL-UHFFFAOYSA-N 2-[2-cyclobutyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]-n,n-dimethylacetamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC(=O)N(C)C)C2=C3CN(CC2)C2CCC2)C3=C1 FQGMRZAPDZONKL-UHFFFAOYSA-N 0.000 claims 1
- IATFUJAKZIVKNY-UHFFFAOYSA-N 2-[2-cyclopentyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]-n,n-dimethylacetamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC(=O)N(C)C)C2=C3CN(CC2)C2CCCC2)C3=C1 IATFUJAKZIVKNY-UHFFFAOYSA-N 0.000 claims 1
- WXCRMQBQSUHIBE-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C1C=2C3=CC(C(=O)N4CC5=CC=CC=C5CC4)=CC=C3N(C)C=2CCN1C1CCOCC1 WXCRMQBQSUHIBE-UHFFFAOYSA-N 0.000 claims 1
- PYCWOQNHNUNSCO-UHFFFAOYSA-N 5-methyl-2-(oxan-4-yl)-n-(oxolan-2-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)NCC1CCCO1 PYCWOQNHNUNSCO-UHFFFAOYSA-N 0.000 claims 1
- QKPOUOPBYLWICG-UHFFFAOYSA-N 5-methyl-2-(oxan-4-yl)-n-phenyl-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)NC1=CC=CC=C1 QKPOUOPBYLWICG-UHFFFAOYSA-N 0.000 claims 1
- PVXROYBDZVXUHK-UHFFFAOYSA-N 5-methyl-n,2-bis(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)NC1CCOCC1 PVXROYBDZVXUHK-UHFFFAOYSA-N 0.000 claims 1
- PZVRJTKRUPRNFN-UHFFFAOYSA-N 5-methyl-n-(2-morpholin-4-ylethyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)NCCN1CCOCC1 PZVRJTKRUPRNFN-UHFFFAOYSA-N 0.000 claims 1
- IOWBXOSMHOXQDB-UHFFFAOYSA-N [2-(2,2-difluoroethyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCN(CC(F)F)CC=3C2=CC=1C(=O)N1CCC(C)CC1 IOWBXOSMHOXQDB-UHFFFAOYSA-N 0.000 claims 1
- YVPLQCQGUWWNJU-UHFFFAOYSA-N [2-(3,4-dihydro-2h-pyrrol-5-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCN(C=4CCCN=4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 YVPLQCQGUWWNJU-UHFFFAOYSA-N 0.000 claims 1
- XXLZMYGIMDUGFJ-UHFFFAOYSA-N [2-(cyclohex-3-en-1-ylmethyl)-5-(2-methoxyethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1CCC=CC1 XXLZMYGIMDUGFJ-UHFFFAOYSA-N 0.000 claims 1
- YHQGAWLEACLMCR-UHFFFAOYSA-N [2-(cyclopentylmethyl)-5-(2-methoxyethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1CCCC1 YHQGAWLEACLMCR-UHFFFAOYSA-N 0.000 claims 1
- VBJGLKTVMGKWFI-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-(2-methoxyethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1CC1 VBJGLKTVMGKWFI-UHFFFAOYSA-N 0.000 claims 1
- HFBGPIKGKKTFBM-UHFFFAOYSA-N [2-(cyclopropylmethyl)-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(S(=O)(=O)CC)C=2CCN1CC1CC1 HFBGPIKGKKTFBM-UHFFFAOYSA-N 0.000 claims 1
- ZUNDGXRVRUQRJI-UHFFFAOYSA-N [2-butyl-5-(2-methoxyethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1N(CCCC)CCC(N(C2=CC=3)CCOC)=C1C2=CC=3C(=O)N1CCC(C)CC1 ZUNDGXRVRUQRJI-UHFFFAOYSA-N 0.000 claims 1
- OGKIWQFBLNEINR-UHFFFAOYSA-N [2-cyclobutyl-5-[(4-ethoxyphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C1CCC1)C2 OGKIWQFBLNEINR-UHFFFAOYSA-N 0.000 claims 1
- UDIRIXGUGDFPAY-UHFFFAOYSA-N [2-ethanimidoyl-5-[(4-ethoxyphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C(C)=N)C2 UDIRIXGUGDFPAY-UHFFFAOYSA-N 0.000 claims 1
- FWPFVGLCWNBZIF-UHFFFAOYSA-N [2-ethyl-5-(2-methoxyethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1N(CC)CCC(N(C2=CC=3)CCOC)=C1C2=CC=3C(=O)N1CCC(C)CC1 FWPFVGLCWNBZIF-UHFFFAOYSA-N 0.000 claims 1
- SAFSKHQXFTWUJK-UHFFFAOYSA-N [4-(hydroxymethyl)piperidin-1-yl]-[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(CO)CC1 SAFSKHQXFTWUJK-UHFFFAOYSA-N 0.000 claims 1
- YBOVBIAZLZRDGP-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(1,3-oxazol-2-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=NC=CO1 YBOVBIAZLZRDGP-UHFFFAOYSA-N 0.000 claims 1
- KDKDNEZHXBKKNN-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(1,3-oxazol-5-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=CN=CO1 KDKDNEZHXBKKNN-UHFFFAOYSA-N 0.000 claims 1
- XACIQXDBFIHLJV-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(2-phenylethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CCC1=CC=CC=C1 XACIQXDBFIHLJV-UHFFFAOYSA-N 0.000 claims 1
- KSSSCUZZJNSZRZ-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(3-methylbutyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCOC)C=3CCN(CCC(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 KSSSCUZZJNSZRZ-UHFFFAOYSA-N 0.000 claims 1
- YFLPKNCLBKTTPE-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(oxolan-3-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1CCOC1 YFLPKNCLBKTTPE-UHFFFAOYSA-N 0.000 claims 1
- TWJOITXWBYBDFM-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(pyridin-2-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=CC=CC=N1 TWJOITXWBYBDFM-UHFFFAOYSA-N 0.000 claims 1
- IAVCVRKOGQTCMO-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(pyridin-3-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=CC=CN=C1 IAVCVRKOGQTCMO-UHFFFAOYSA-N 0.000 claims 1
- LVUOGTGREOXLGT-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-(pyridin-4-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=CC=NC=C1 LVUOGTGREOXLGT-UHFFFAOYSA-N 0.000 claims 1
- KDZHTILKLKVWMZ-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-[(6-methylpyridin-2-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CC1=CC=CC(C)=N1 KDZHTILKLKVWMZ-UHFFFAOYSA-N 0.000 claims 1
- VNHOGLXSCJDQLM-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-[2-(oxan-4-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1C=2C3=CC(C(=O)N4CCC(C)CC4)=CC=C3N(CCOC)C=2CCN1CCC1CCOCC1 VNHOGLXSCJDQLM-UHFFFAOYSA-N 0.000 claims 1
- ZQDOPMGIVQTNST-UHFFFAOYSA-N [5-(2-methoxyethyl)-2-pentyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1N(CCCCC)CCC(N(C2=CC=3)CCOC)=C1C2=CC=3C(=O)N1CCC(C)CC1 ZQDOPMGIVQTNST-UHFFFAOYSA-N 0.000 claims 1
- UCMNIYFDRVBMFV-UHFFFAOYSA-N [5-ethylsulfonyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 UCMNIYFDRVBMFV-UHFFFAOYSA-N 0.000 claims 1
- SRVUHZJXAYHXIN-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N(C)C2=C3CN(CC2)C2CCOCC2)C3=C1 SRVUHZJXAYHXIN-UHFFFAOYSA-N 0.000 claims 1
- IGBCISBWUNCTNY-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C)C2=C3CN(CC2)C2CCOCC2)C3=C1 IGBCISBWUNCTNY-UHFFFAOYSA-N 0.000 claims 1
- CIYIQMUKJDTYAJ-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-phenylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N(CC1)CCC1C1=CC=CC=C1 CIYIQMUKJDTYAJ-UHFFFAOYSA-N 0.000 claims 1
- OPYPOQONOBJLPD-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-[4-(trifluoromethyl)piperidin-1-yl]methanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCC(C(F)(F)F)CC1 OPYPOQONOBJLPD-UHFFFAOYSA-N 0.000 claims 1
- VSHOWHRCWOIRAS-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-morpholin-4-ylmethanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCOCC1 VSHOWHRCWOIRAS-UHFFFAOYSA-N 0.000 claims 1
- AWPMNXJSXFCGSV-UHFFFAOYSA-N [5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-piperidin-1-ylmethanone Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N1CCCCC1 AWPMNXJSXFCGSV-UHFFFAOYSA-N 0.000 claims 1
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- YBBYEWHGGOBZTP-UHFFFAOYSA-N methyl 2-[2-cyclobutyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]acetate Chemical compound C=1C=C2N(CC(=O)OC)C=3CCN(C4CCC4)CC=3C2=CC=1C(=O)N1CCC(C)CC1 YBBYEWHGGOBZTP-UHFFFAOYSA-N 0.000 claims 1
- VSHCLFPRPOXBBF-UHFFFAOYSA-N methyl 2-[[8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]sulfonyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)N1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C1CCOCC1)C2 VSHCLFPRPOXBBF-UHFFFAOYSA-N 0.000 claims 1
- CPSQTBKLWRCGBX-UHFFFAOYSA-N n-(2-hydroxyethyl)-n,5-dimethyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)N(CCO)C)=CC=C3N(C)C=2CCN1C1CCOCC1 CPSQTBKLWRCGBX-UHFFFAOYSA-N 0.000 claims 1
- OMORGSGQZVTEBA-UHFFFAOYSA-N n-(2-methoxyethyl)-5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)NCCOC)=CC=C3N(C)C=2CCN1C1CCOCC1 OMORGSGQZVTEBA-UHFFFAOYSA-N 0.000 claims 1
- QOQAZIKTQNXQFU-UHFFFAOYSA-N n-[2-(dimethylamino)-2-oxoethyl]-n,5-dimethyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)N(C)CC(=O)N(C)C)=CC=C3N(C)C=2CCN1C1CCOCC1 QOQAZIKTQNXQFU-UHFFFAOYSA-N 0.000 claims 1
- IRISXNLIJVWQSO-UHFFFAOYSA-N n-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]cyclobutanecarboxamide Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCC1 IRISXNLIJVWQSO-UHFFFAOYSA-N 0.000 claims 1
- BHMCZXLTPFVNMC-UHFFFAOYSA-N n-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]cyclopentanecarboxamide Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCCC1 BHMCZXLTPFVNMC-UHFFFAOYSA-N 0.000 claims 1
- GWTOBOYCYQCJHL-UHFFFAOYSA-N n-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]oxane-4-carboxamide Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCOCC1 GWTOBOYCYQCJHL-UHFFFAOYSA-N 0.000 claims 1
- WFEBRTGBKHHFBW-UHFFFAOYSA-N n-[2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]oxolane-2-carboxamide Chemical compound C=1C=C2N(CCC)C=3CCN(C4CCOCC4)CC=3C2=CC=1NC(=O)C1CCCO1 WFEBRTGBKHHFBW-UHFFFAOYSA-N 0.000 claims 1
- KNFLDURHTRCKTJ-UHFFFAOYSA-N n-ethyl-5-methyl-2-(oxan-4-yl)-n-(pyridin-4-ylmethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)N(CC)CC1=CC=NC=C1 KNFLDURHTRCKTJ-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 759
- 239000000243 solution Substances 0.000 description 213
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 211
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 151
- 239000002904 solvent Substances 0.000 description 137
- 238000005160 1H NMR spectroscopy Methods 0.000 description 121
- 239000000047 product Substances 0.000 description 117
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 94
- 239000012043 crude product Substances 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 83
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 78
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 71
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 66
- 239000011541 reaction mixture Substances 0.000 description 65
- 239000011734 sodium Substances 0.000 description 65
- 238000004007 reversed phase HPLC Methods 0.000 description 62
- 238000000746 purification Methods 0.000 description 59
- 229920006395 saturated elastomer Polymers 0.000 description 55
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 54
- 229910052938 sodium sulfate Inorganic materials 0.000 description 54
- 235000011152 sodium sulphate Nutrition 0.000 description 54
- 238000002360 preparation method Methods 0.000 description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000007858 starting material Substances 0.000 description 45
- 239000007787 solid Substances 0.000 description 44
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 42
- 238000002953 preparative HPLC Methods 0.000 description 40
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 239000000725 suspension Substances 0.000 description 31
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 30
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 26
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 22
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 0 *c(cc1)cc2c1[n](*)c1c2CN(*)CC1 Chemical compound *c(cc1)cc2c1[n](*)c1c2CN(*)CC1 0.000 description 13
- VERAMZSNHKPFHT-UHFFFAOYSA-N 2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-amine Chemical compound C1C2C3=CC(N)=CC=C3N(CCC)C2CCN1C1CCCC1 VERAMZSNHKPFHT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 12
- 150000003840 hydrochlorides Chemical class 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 description 8
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical compound C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical group OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- LCLGLPDRQJBJET-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxylic acid Chemical compound N1C2=CC=C(C(O)=O)C=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 LCLGLPDRQJBJET-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 5
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- KVQMGTLPXXNPBJ-UHFFFAOYSA-N (4-methoxypiperidin-1-yl)-(2-propan-2-yl-1,3,4,5-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C1=CC=C(NC2=C3CN(CC2)C(C)C)C3=C1 KVQMGTLPXXNPBJ-UHFFFAOYSA-N 0.000 description 4
- FTPVSCIGAHEPHR-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-prop-2-enyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CNCC2)C3=C1 FTPVSCIGAHEPHR-UHFFFAOYSA-N 0.000 description 4
- SYFDTBGGGZOURA-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-propyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(CCC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 SYFDTBGGGZOURA-UHFFFAOYSA-N 0.000 description 4
- UTMIEQASUFFADK-UHFFFAOYSA-N 3,3,3-trifluoropropanal Chemical compound FC(F)(F)CC=O UTMIEQASUFFADK-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CKXQVWPQEWOESG-UHFFFAOYSA-N (4,4-difluoropiperidin-1-yl)-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(C)C=3CCNCC=3C2=CC=1C(=O)N1CCC(F)(F)CC1 CKXQVWPQEWOESG-UHFFFAOYSA-N 0.000 description 3
- YJWZDGPMZYIBPN-UHFFFAOYSA-N (5-ethylsulfonyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 YJWZDGPMZYIBPN-UHFFFAOYSA-N 0.000 description 3
- DCLMJYZEOSDVCL-UHFFFAOYSA-N 1-(chloromethyl)-4-ethoxybenzene Chemical compound CCOC1=CC=C(CCl)C=C1 DCLMJYZEOSDVCL-UHFFFAOYSA-N 0.000 description 3
- IPONLHAIQBCUCY-UHFFFAOYSA-N 1h-indole;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC=CC2=C1 IPONLHAIQBCUCY-UHFFFAOYSA-N 0.000 description 3
- WYZFLCYTROCEOJ-UHFFFAOYSA-N 1h-pyrido[4,3-b]indole Chemical compound C1=CC=CC2=C3CN=CC=C3N=C21 WYZFLCYTROCEOJ-UHFFFAOYSA-N 0.000 description 3
- DJBDLEGJSVWQRC-UHFFFAOYSA-N 2-propan-2-yl-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxylic acid Chemical compound N1C2=CC=C(C(O)=O)C=C2C2=C1CCN(C(C)C)C2 DJBDLEGJSVWQRC-UHFFFAOYSA-N 0.000 description 3
- JKEQDXLVXVHUQP-UHFFFAOYSA-N 8-nitro-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical compound C1CNCC2C3=CC([N+](=O)[O-])=CC=C3NC21 JKEQDXLVXVHUQP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- HLZRNGBFYAMADP-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCNC2 HLZRNGBFYAMADP-UHFFFAOYSA-N 0.000 description 3
- KOSPEENVHVOCOY-UHFFFAOYSA-N [5-[(5-methyl-1,2-oxazol-4-yl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2=C(ON=C2)C)C2=C3CNCC2)C3=C1 KOSPEENVHVOCOY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- VOSSIGOPQKPUIJ-UHFFFAOYSA-N pyrido[4,3-b]indole-2-carboxylic acid Chemical compound C1=CC=C2C3=CN(C(=O)O)C=CC3=NC2=C1 VOSSIGOPQKPUIJ-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- FFRGDFMGCUUXNI-UHFFFAOYSA-N tert-butyl 5-ethylsulfonyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 FFRGDFMGCUUXNI-UHFFFAOYSA-N 0.000 description 3
- BLQRPBJXYGOMQZ-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(NC2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 BLQRPBJXYGOMQZ-UHFFFAOYSA-N 0.000 description 3
- LTZXAHHHMKFVBQ-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(CCC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 LTZXAHHHMKFVBQ-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- UKFLLQIRBABMKF-UHFFFAOYSA-N (4-ethoxyphenyl)methanol Chemical compound CCOC1=CC=C(CO)C=C1 UKFLLQIRBABMKF-UHFFFAOYSA-N 0.000 description 2
- SRMFXGFNVRFAON-UHFFFAOYSA-N (4-ethoxypiperidin-1-yl)-(2-propan-2-yl-1,3,4,5-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(OCC)CCN1C(=O)C1=CC=C(NC2=C3CN(CC2)C(C)C)C3=C1 SRMFXGFNVRFAON-UHFFFAOYSA-N 0.000 description 2
- JRWMDDNWHILBFA-UHFFFAOYSA-N (5-cyclopropylsulfonyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CNCC2)S(=O)(=O)C2CC2)C3=C1 JRWMDDNWHILBFA-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- WNPFDMGMNSMOMD-UHFFFAOYSA-M 1-imidazol-1-ylsulfonyl-3-methylimidazol-3-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C1=[N+](C)C=CN1S(=O)(=O)N1C=NC=C1 WNPFDMGMNSMOMD-UHFFFAOYSA-M 0.000 description 2
- KXUGUWTUFUWYRS-UHFFFAOYSA-N 1-methylimidazole-4-sulfonyl chloride Chemical compound CN1C=NC(S(Cl)(=O)=O)=C1 KXUGUWTUFUWYRS-UHFFFAOYSA-N 0.000 description 2
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 2
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- QYGNDKJRRNVSEC-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-pyrrole Chemical compound COC1=NCCC1 QYGNDKJRRNVSEC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- WANVBQLJIYLMFC-UHFFFAOYSA-N 8-nitro-2-(oxan-4-yl)-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound C1C2C3=CC([N+](=O)[O-])=CC=C3NC2CCN1C1CCOCC1 WANVBQLJIYLMFC-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OWISCCRXKXYGAI-UHFFFAOYSA-N CC(CC1)CCN1C(c1ccc2[n](CC(OC)=O)c(CCNC3)c3c2c1)=O Chemical compound CC(CC1)CCN1C(c1ccc2[n](CC(OC)=O)c(CCNC3)c3c2c1)=O OWISCCRXKXYGAI-UHFFFAOYSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- QKJLIBJQEHNDAY-UHFFFAOYSA-N [5-(cyclopropylmethyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CC2)C2=C3CNCC2)C3=C1 QKJLIBJQEHNDAY-UHFFFAOYSA-N 0.000 description 2
- XCPQEHKBDTXLOB-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-yl]-(4-ethoxypiperidin-1-yl)methanone Chemical compound C1CC(OCC)CCN1C(=O)C1=CC=C(N(CC=2C=CC(OCC)=CC=2)C2=C3CN(CC2)C(C)C)C3=C1 XCPQEHKBDTXLOB-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- CTKWYMDQHZYKNC-UHFFFAOYSA-N methyl 5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indole-8-carboxylate Chemical compound C1CNCC2=C1N(C)C1=CC=C(C(=O)OC)C=C12 CTKWYMDQHZYKNC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 2
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XRDXMZWJKHLVFU-UHFFFAOYSA-N tert-butyl 5-[2-(dimethylamino)-2-oxoethyl]-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC(=O)N(C)C)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 XRDXMZWJKHLVFU-UHFFFAOYSA-N 0.000 description 2
- CVOQOTRYPDMPRU-UHFFFAOYSA-N tert-butyl 5-butanoyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(C(=O)CCC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 CVOQOTRYPDMPRU-UHFFFAOYSA-N 0.000 description 2
- DWNOJWJDTDZROS-UHFFFAOYSA-N tert-butyl 5-ethylsulfonyl-8-(pyrrolidine-1-carbonylamino)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1NC(=O)N1CCCC1 DWNOJWJDTDZROS-UHFFFAOYSA-N 0.000 description 2
- BAAZLDZLJCCAJW-UHFFFAOYSA-N tert-butyl 5-methyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 BAAZLDZLJCCAJW-UHFFFAOYSA-N 0.000 description 2
- VAZCFPIQUYYILW-UHFFFAOYSA-N tert-butyl 5-methylsulfonyl-8-nitro-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound [O-][N+](=O)C1=CC=C2N(S(C)(=O)=O)C3CCN(C(=O)OC(C)(C)C)CC3C2=C1 VAZCFPIQUYYILW-UHFFFAOYSA-N 0.000 description 2
- SOCGTSFSCUQGSP-UHFFFAOYSA-N tert-butyl 8-(3-methylpiperidine-1-carbonyl)-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1C(C)CCCN1C(=O)C1=CC=C(NC2C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 SOCGTSFSCUQGSP-UHFFFAOYSA-N 0.000 description 2
- VAHBNJPYGJFMFM-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 VAHBNJPYGJFMFM-UHFFFAOYSA-N 0.000 description 2
- UGVBNILJAWKXPB-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-propan-2-ylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)C(C)C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 UGVBNILJAWKXPB-UHFFFAOYSA-N 0.000 description 2
- PNXSOWYXRVTFIQ-UHFFFAOYSA-N tert-butyl 8-amino-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC(N)=CC=C2N(S(=O)(=O)CC)C2=C1CN(C(=O)OC(C)(C)C)CC2 PNXSOWYXRVTFIQ-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- CQGGYJVZDANBIG-UHFFFAOYSA-N (4-methoxy-3-phenylmethoxyphenyl)methylhydrazine Chemical compound COC1=CC=C(CNN)C=C1OCC1=CC=CC=C1 CQGGYJVZDANBIG-UHFFFAOYSA-N 0.000 description 1
- YELTZRZYHKRMBC-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(NC2=C3CNCC2)C3=C1 YELTZRZYHKRMBC-UHFFFAOYSA-N 0.000 description 1
- BJOGUADNGSYHKN-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C)C2=C3CNCC2)C3=C1 BJOGUADNGSYHKN-UHFFFAOYSA-N 0.000 description 1
- QGGCHIRDRGZVAG-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-methylsulfonyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CNCC2)S(C)(=O)=O)C3=C1 QGGCHIRDRGZVAG-UHFFFAOYSA-N 0.000 description 1
- JVGOYWWAVZMZMQ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-propan-2-ylsulfonyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)C(C)C)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 JVGOYWWAVZMZMQ-UHFFFAOYSA-N 0.000 description 1
- PNMWAQIPYJDQHN-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-propylsulfonyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)methanone Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 PNMWAQIPYJDQHN-UHFFFAOYSA-N 0.000 description 1
- IBPUEJUNVGTVJJ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-(4-nitrophenyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CNCC2)C=2C=CC(=CC=2)[N+]([O-])=O)C3=C1 IBPUEJUNVGTVJJ-UHFFFAOYSA-N 0.000 description 1
- IXJBOKLOKDOYKG-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-[(2-methyl-1,3-thiazol-4-yl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2N=C(C)SC=2)C2=C3CNCC2)C3=C1 IXJBOKLOKDOYKG-UHFFFAOYSA-N 0.000 description 1
- UMPFKCITXSZXDL-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-[(4-methylsulfanylphenyl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]methanone Chemical compound C1=CC(SC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCNC2 UMPFKCITXSZXDL-UHFFFAOYSA-N 0.000 description 1
- FBQNTKCVQULCNS-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-[(4-methylsulfonylphenyl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2C=CC(=CC=2)S(C)(=O)=O)C2=C3CNCC2)C3=C1 FBQNTKCVQULCNS-UHFFFAOYSA-N 0.000 description 1
- MTXQKSQYMREAGJ-UHFFFAOYSA-N (4-methylsulfanylphenyl)methanol Chemical compound CSC1=CC=C(CO)C=C1 MTXQKSQYMREAGJ-UHFFFAOYSA-N 0.000 description 1
- AYFKJYSFSSBIQA-UHFFFAOYSA-N (5-ethyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 AYFKJYSFSSBIQA-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical compound C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 description 1
- WGLZPTYNHCWRKX-UHFFFAOYSA-N 1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1CCN(C(=O)O)C2 WGLZPTYNHCWRKX-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- CZLMRJZAHXYRIX-UHFFFAOYSA-N 1,3-dioxepane Chemical compound C1CCOCOC1 CZLMRJZAHXYRIX-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- LXPRVXKHIXWBJZ-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(CCl)C=C1 LXPRVXKHIXWBJZ-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- NWPXMGNZTWTDAE-UHFFFAOYSA-N 1-[8-(4-methylpiperidine-1-carbonyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl]butan-1-one Chemical compound C=1C=C2N(C(=O)CCC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 NWPXMGNZTWTDAE-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- CCDBCHAQIXKJCG-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-one Chemical compound CC(C)N1CCC(=O)CC1 CCDBCHAQIXKJCG-UHFFFAOYSA-N 0.000 description 1
- ZLTWIJREHQCJJL-UHFFFAOYSA-N 1-trimethylsilylethanol Chemical compound CC(O)[Si](C)(C)C ZLTWIJREHQCJJL-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- PMWGIVRHUIAIII-UHFFFAOYSA-N 2,2-difluoropropanoic acid Chemical compound CC(F)(F)C(O)=O PMWGIVRHUIAIII-UHFFFAOYSA-N 0.000 description 1
- YHCUZRJTNSWYCY-UHFFFAOYSA-N 2,3,4,7-tetrahydro-1h-azepine Chemical compound C1CNCC=CC1 YHCUZRJTNSWYCY-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- LSXJPJGBWSZHTM-UHFFFAOYSA-N 2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CBr LSXJPJGBWSZHTM-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- AZMIGSMKZQATGU-UHFFFAOYSA-N 2-(oxan-4-yl)-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-amine Chemical compound C1C=2C3=CC(N)=CC=C3N(CCC)C=2CCN1C1CCOCC1 AZMIGSMKZQATGU-UHFFFAOYSA-N 0.000 description 1
- YHDOPAFTINLGMB-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl]-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole-8-carboxylic acid Chemical compound N1C2=CC=C(C(O)=O)C=C2C2C1CCN(C(=O)OC(C)(C)C)C2 YHDOPAFTINLGMB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AGVHYIFQWMKQLX-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]sulfonylacetonitrile Chemical compound FC(F)(F)C1=CC=C(S(=O)(=O)CC#N)C=C1 AGVHYIFQWMKQLX-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- GNECRNGWCZNOIF-UHFFFAOYSA-N 2-cyclobutyl-n,n-dimethyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-5-sulfonamide Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C2CCC2)S(=O)(=O)N(C)C)C3=C1 GNECRNGWCZNOIF-UHFFFAOYSA-N 0.000 description 1
- KWSSNJLHQGJAEG-UHFFFAOYSA-N 2-cyclopentyl-5-propyl-3,4-dihydro-1h-pyrido[4,3-b]indol-8-amine Chemical compound C1C=2C3=CC(N)=CC=C3N(CCC)C=2CCN1C1CCCC1 KWSSNJLHQGJAEG-UHFFFAOYSA-N 0.000 description 1
- PGILMFLYBAIYRW-UHFFFAOYSA-N 2-cyclopentyl-8-(dimethylsulfamoylamino)-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indole Chemical compound C1C2C3=CC(NS(=O)(=O)N(C)C)=CC=C3N(CCC)C2CCN1C1CCCC1 PGILMFLYBAIYRW-UHFFFAOYSA-N 0.000 description 1
- JYQCIPWCRIRZHI-UHFFFAOYSA-N 2-cyclopentyl-8-nitro-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound C1C2C3=CC([N+](=O)[O-])=CC=C3NC2CCN1C1CCCC1 JYQCIPWCRIRZHI-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical group C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical compound CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- JOWXBGIZDALBJW-UHFFFAOYSA-N 3h-dioxepine Chemical compound C1OOC=CC=C1 JOWXBGIZDALBJW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LMOOYAKLEOGKJR-UHFFFAOYSA-N 4-(bromomethyl)oxane Chemical compound BrCC1CCOCC1 LMOOYAKLEOGKJR-UHFFFAOYSA-N 0.000 description 1
- AQBBZYVPKBIILN-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole Chemical compound CC1=NC(CCl)=CS1 AQBBZYVPKBIILN-UHFFFAOYSA-N 0.000 description 1
- OAPPWKBQKZMFCB-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1,2-oxazole Chemical compound CC=1ON=CC=1CCl OAPPWKBQKZMFCB-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- OYHQAXYDSYSGEI-UHFFFAOYSA-N 4-ethoxypiperidine Chemical compound CCOC1CCNCC1 OYHQAXYDSYSGEI-UHFFFAOYSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- ZEYSHALLPAKUHG-UHFFFAOYSA-N 4-methoxypiperidine Chemical compound COC1CCNCC1 ZEYSHALLPAKUHG-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- APJKOQPCHGXQBI-UHFFFAOYSA-N 5-chloro-6-(chloromethyl)-1,3-benzodioxole Chemical compound C1=C(Cl)C(CCl)=CC2=C1OCO2 APJKOQPCHGXQBI-UHFFFAOYSA-N 0.000 description 1
- IVHSDYANQJWUGR-UHFFFAOYSA-N 5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxylic acid Chemical compound C1C=2C3=CC(C(O)=O)=CC=C3N(C)C=2CCN1C1CCOCC1 IVHSDYANQJWUGR-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- YPWFNLSXQIGJCK-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 description 1
- 125000005941 7-oxabicyclo[2.2.1]heptyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UGIZUUWFYMGZSZ-UHFFFAOYSA-N C(C)OC1=CC=C(CN2C3=C(C=4C=C(C=CC24)C(=O)N2CCC(CC2)C)CN(CC3)C(=O)OC(C)(C)C)C=C1.Cl Chemical compound C(C)OC1=CC=C(CN2C3=C(C=4C=C(C=CC24)C(=O)N2CCC(CC2)C)CN(CC3)C(=O)OC(C)(C)C)C=C1.Cl UGIZUUWFYMGZSZ-UHFFFAOYSA-N 0.000 description 1
- OBHLAVNKOLIBRQ-YZNYGJBQSA-N C/C=C\C(\S(N(C)c1ccc2[n](CC=C)c(CCNC3)c3c2c1)(=O)=O)=C/C Chemical compound C/C=C\C(\S(N(C)c1ccc2[n](CC=C)c(CCNC3)c3c2c1)(=O)=O)=C/C OBHLAVNKOLIBRQ-YZNYGJBQSA-N 0.000 description 1
- JFRZONFRKOZIJM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)Cc2c1[nH]c(cc1)c2cc1C(N(CC1)Cc2c1cccc2)=O)=O Chemical compound CC(C)(C)OC(N(CC1)Cc2c1[nH]c(cc1)c2cc1C(N(CC1)Cc2c1cccc2)=O)=O JFRZONFRKOZIJM-UHFFFAOYSA-N 0.000 description 1
- UXFMWGUCLMVQRM-UHFFFAOYSA-N CC(CC1)CCN1C(c(cc1)cc(c(C2)c3CCN2C2CCOCC2)c1[n]3S(C)(=C)=O)=O Chemical compound CC(CC1)CCN1C(c(cc1)cc(c(C2)c3CCN2C2CCOCC2)c1[n]3S(C)(=C)=O)=O UXFMWGUCLMVQRM-UHFFFAOYSA-N 0.000 description 1
- UOULYTUAIJMLHT-UHFFFAOYSA-N CC(CC1)CCN1C(c(cc1)cc2c1[n](Cc1ccccn1)c(CC1)c2CN1C(OC(C)(C)C)=O)=O Chemical compound CC(CC1)CCN1C(c(cc1)cc2c1[n](Cc1ccccn1)c(CC1)c2CN1C(OC(C)(C)C)=O)=O UOULYTUAIJMLHT-UHFFFAOYSA-N 0.000 description 1
- ZGVVSKIBXOLXJW-UHFFFAOYSA-N CC(CC1)CCN1C(c(cc1c2c3CCN(C)C2)ccc1[n]3S(C1CC1)(=O)=O)=O Chemical compound CC(CC1)CCN1C(c(cc1c2c3CCN(C)C2)ccc1[n]3S(C1CC1)(=O)=O)=O ZGVVSKIBXOLXJW-UHFFFAOYSA-N 0.000 description 1
- IVYZZIPECXAFKR-UHFFFAOYSA-N CC(CC1)CCN1C(c1ccc2[nH]c(CCN(C3)C4CCOCC4)c3c2c1)=O Chemical compound CC(CC1)CCN1C(c1ccc2[nH]c(CCN(C3)C4CCOCC4)c3c2c1)=O IVYZZIPECXAFKR-UHFFFAOYSA-N 0.000 description 1
- DVKVZLHHDGAOPJ-UHFFFAOYSA-N CC(CC1)CCN1C(c1ccc2[n](CC(N(C)C)=O)c(CCNC3)c3c2c1)=O Chemical compound CC(CC1)CCN1C(c1ccc2[n](CC(N(C)C)=O)c(CCNC3)c3c2c1)=O DVKVZLHHDGAOPJ-UHFFFAOYSA-N 0.000 description 1
- WMKDRGRUMSIVFU-UHFFFAOYSA-N CC(CC1)CCN1C(c1ccc2[n](CC(OC)=O)c(CCN(C3)C4CCCCC4)c3c2c1)=O Chemical compound CC(CC1)CCN1C(c1ccc2[n](CC(OC)=O)c(CCN(C3)C4CCCCC4)c3c2c1)=O WMKDRGRUMSIVFU-UHFFFAOYSA-N 0.000 description 1
- POMSQEMIFCGDNY-UHFFFAOYSA-N CC(CC1)CCN1C(c1ccc2[n](CC=C)c(CCN(C3)C(C4CCOCC4)=O)c3c2c1)=O Chemical compound CC(CC1)CCN1C(c1ccc2[n](CC=C)c(CCN(C3)C(C4CCOCC4)=O)c3c2c1)=O POMSQEMIFCGDNY-UHFFFAOYSA-N 0.000 description 1
- NNDZIIYUTVDZAG-UHFFFAOYSA-O CC(CC1)CC[NH+]1C(c1ccc2[n](CC3CC3)c(CCN(C3)C(OC(C)(C)C)=O)c3c2c1)=O Chemical compound CC(CC1)CC[NH+]1C(c1ccc2[n](CC3CC3)c(CCN(C3)C(OC(C)(C)C)=O)c3c2c1)=O NNDZIIYUTVDZAG-UHFFFAOYSA-O 0.000 description 1
- WNUVUEKGFFSKLR-ODCIPOBUSA-N CC/C(/C(N1CCC(C)CC1)=O)=C\CC(NCC1)=C1NCc(cc1)ccc1OCC Chemical compound CC/C(/C(N1CCC(C)CC1)=O)=C\CC(NCC1)=C1NCc(cc1)ccc1OCC WNUVUEKGFFSKLR-ODCIPOBUSA-N 0.000 description 1
- OEOOSSRBEQVWLO-UHFFFAOYSA-N CC1ON=CC1C[n](c(CCN(C1)C(OC(C)(C)C)=O)c1c1c2)c1ccc2C(N1CCC(C)CC1)=O Chemical compound CC1ON=CC1C[n](c(CCN(C1)C(OC(C)(C)C)=O)c1c1c2)c1ccc2C(N1CCC(C)CC1)=O OEOOSSRBEQVWLO-UHFFFAOYSA-N 0.000 description 1
- LQBZICVHJNWPNJ-UHFFFAOYSA-N CCC[n](c(CCN(C1)C2CCCC2)c1c1c2)c1ccc2NS(c1ccccc1)(=O)=O Chemical compound CCC[n](c(CCN(C1)C2CCCC2)c1c1c2)c1ccc2NS(c1ccccc1)(=O)=O LQBZICVHJNWPNJ-UHFFFAOYSA-N 0.000 description 1
- SVEHLSOYKRTKKV-UHFFFAOYSA-N CCC[n](c(CCN(C1)C2CCOCC2)c1c1c2)c1ccc2N(C)S(c1ccccc1)(=O)=O Chemical compound CCC[n](c(CCN(C1)C2CCOCC2)c1c1c2)c1ccc2N(C)S(c1ccccc1)(=O)=O SVEHLSOYKRTKKV-UHFFFAOYSA-N 0.000 description 1
- KXCCLVIVQIQLRO-UHFFFAOYSA-N CCOC(C[n](c(CCN(C1)C(OC(C)(C)C)=O)c1c1c2)c1ccc2C(N1CCC(C)CC1)=O)=O Chemical compound CCOC(C[n](c(CCN(C1)C(OC(C)(C)C)=O)c1c1c2)c1ccc2C(N1CCC(C)CC1)=O)=O KXCCLVIVQIQLRO-UHFFFAOYSA-N 0.000 description 1
- FANDRITVNFVDDL-UHFFFAOYSA-N CCOC1(C)C=CC(C[n](c(CCNC2)c2c2c3)c2ccc3C(N2CCC(C)CC2)=O)=CC1 Chemical compound CCOC1(C)C=CC(C[n](c(CCNC2)c2c2c3)c2ccc3C(N2CCC(C)CC2)=O)=CC1 FANDRITVNFVDDL-UHFFFAOYSA-N 0.000 description 1
- XXAUEDHAQGJMHK-UHFFFAOYSA-N CCOC1(C)C=CC(C[n]2c(ccc(C(N3CCC(C)CC3)=O)c3)c3c(C3)c2CCN3C2CCC2)=CC1 Chemical compound CCOC1(C)C=CC(C[n]2c(ccc(C(N3CCC(C)CC3)=O)c3)c3c(C3)c2CCN3C2CCC2)=CC1 XXAUEDHAQGJMHK-UHFFFAOYSA-N 0.000 description 1
- RMGXYCKUQHJSMA-UHFFFAOYSA-N CCOc1ccc(C[n](c(CCN(C2)C3CCCC3)c2c2c3)c2ccc3C(N2CCC(C)CC2)=O)cc1 Chemical compound CCOc1ccc(C[n](c(CCN(C2)C3CCCC3)c2c2c3)c2ccc3C(N2CCC(C)CC2)=O)cc1 RMGXYCKUQHJSMA-UHFFFAOYSA-N 0.000 description 1
- POSDLCJRUFJAFT-UHFFFAOYSA-O CN(C1)C1[NH+](CCC12)CC1c1cc([N+]([O-])=O)ccc1N2S(C)(=O)=O Chemical compound CN(C1)C1[NH+](CCC12)CC1c1cc([N+]([O-])=O)ccc1N2S(C)(=O)=O POSDLCJRUFJAFT-UHFFFAOYSA-O 0.000 description 1
- CHCXHANLBSZPQC-UHFFFAOYSA-N CN(c1ccc2[n](C=C=C)c(CCN(C3)C4CCOCC4)c3c2c1)S(c1ccccc1)(=O)=O Chemical compound CN(c1ccc2[n](C=C=C)c(CCN(C3)C4CCOCC4)c3c2c1)S(c1ccccc1)(=O)=O CHCXHANLBSZPQC-UHFFFAOYSA-N 0.000 description 1
- JSWKEVJNJDKZDH-UHFFFAOYSA-N CN(c1ccc2[n](CC=C)c(CCN(C3)C4CCCC4)c3c2c1)S(c1ccccc1)(=O)=O Chemical compound CN(c1ccc2[n](CC=C)c(CCN(C3)C4CCCC4)c3c2c1)S(c1ccccc1)(=O)=O JSWKEVJNJDKZDH-UHFFFAOYSA-N 0.000 description 1
- CNJQXKQMEWJMAE-UHFFFAOYSA-N CN(c1ccc2[n](CC=C)c(CCN(C3)C4CCOCC4)c3c2c1)S(c1ccccc1)(=O)=O Chemical compound CN(c1ccc2[n](CC=C)c(CCN(C3)C4CCOCC4)c3c2c1)S(c1ccccc1)(=O)=O CNJQXKQMEWJMAE-UHFFFAOYSA-N 0.000 description 1
- LFIOFMYCDQKCNF-UHFFFAOYSA-N CN(c1ccc2[n](CC=C)c(CCNC3)c3c2c1)S(c1ccccc1)(=O)=O Chemical compound CN(c1ccc2[n](CC=C)c(CCNC3)c3c2c1)S(c1ccccc1)(=O)=O LFIOFMYCDQKCNF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JYIJLCGEBZRACV-UHFFFAOYSA-N Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 Chemical compound Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 JYIJLCGEBZRACV-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000180094 Vischeria helvetica Species 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- OOLRHWRNECWTFP-UHFFFAOYSA-N [5-(2-methoxyethyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C=1C=C2N(CCOC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 OOLRHWRNECWTFP-UHFFFAOYSA-N 0.000 description 1
- JYKFTPRFJJUZGO-UHFFFAOYSA-N [5-(2-methoxyethyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C=1C=C2N(CCOC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 JYKFTPRFJJUZGO-UHFFFAOYSA-N 0.000 description 1
- BIHVMPOCIUFVPS-UHFFFAOYSA-N [5-(cyclobutylmethyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CCC2)C2=C3CNCC2)C3=C1 BIHVMPOCIUFVPS-UHFFFAOYSA-N 0.000 description 1
- WZYWOYZECFPLEO-UHFFFAOYSA-N [5-[(4-ethoxyphenyl)methyl]-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl]-(4-methylpiperidin-1-yl)methanone;dihydrochloride Chemical compound Cl.Cl.C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCNC2 WZYWOYZECFPLEO-UHFFFAOYSA-N 0.000 description 1
- LUYWOSSOHFNRSP-UHFFFAOYSA-N [chlorosulfonylsulfonyl(methyl)amino]methane Chemical compound CN(C)S(=O)(=O)S(Cl)(=O)=O LUYWOSSOHFNRSP-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ZWWXDCOPVYATOQ-UHFFFAOYSA-N amino-(4-nitrophenyl)azanium;chloride Chemical compound [Cl-].N[NH2+]C1=CC=C([N+]([O-])=O)C=C1 ZWWXDCOPVYATOQ-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- NXHPEFFPWWWGJK-UHFFFAOYSA-N ethyl 2-[8-(4-methylpiperidine-1-carbonyl)-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl]acetate Chemical compound C=1C=C2N(CC(=O)OCC)C=3CCNCC=3C2=CC=1C(=O)N1CCC(C)CC1 NXHPEFFPWWWGJK-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- CZALJDQHONFVFU-UHFFFAOYSA-N isocyanatocyclopentane Chemical compound O=C=NC1CCCC1 CZALJDQHONFVFU-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- IRMHJIZJDBMSQV-UHFFFAOYSA-N methyl 5-methyl-2-(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxylate Chemical compound C1C=2C3=CC(C(=O)OC)=CC=C3N(C)C=2CCN1C1CCOCC1 IRMHJIZJDBMSQV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- KDJXDYICSURWQH-UHFFFAOYSA-N n-(2-cyclopentyl-5-propyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indol-8-yl)cyclopropanesulfonamide Chemical compound C=1C=C2N(CCC)C3CCN(C4CCCC4)CC3C2=CC=1NS(=O)(=O)C1CC1 KDJXDYICSURWQH-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- GSUBXIVOZXWGKF-UHFFFAOYSA-N oxolane-3-carbaldehyde Chemical compound O=CC1CCOC1 GSUBXIVOZXWGKF-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- XACWJIQLDLUFSR-UHFFFAOYSA-N pyrrolidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCC1 XACWJIQLDLUFSR-UHFFFAOYSA-N 0.000 description 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical compound C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 208000016702 sympathetic nervous system disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- LBBHOAICUQFOFO-UHFFFAOYSA-N tert-butyl 5-(2-methoxyethyl)-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(CCOC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 LBBHOAICUQFOFO-UHFFFAOYSA-N 0.000 description 1
- AYADKTNJBDLVRC-UHFFFAOYSA-N tert-butyl 5-(cyclobutylmethyl)-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CCC2)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 AYADKTNJBDLVRC-UHFFFAOYSA-N 0.000 description 1
- NNDZIIYUTVDZAG-UHFFFAOYSA-N tert-butyl 5-(cyclopropylmethyl)-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC2CC2)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 NNDZIIYUTVDZAG-UHFFFAOYSA-N 0.000 description 1
- LPAXDNQKYGLTGT-UHFFFAOYSA-N tert-butyl 5-(ethylsulfamoyl)-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)NCC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 LPAXDNQKYGLTGT-UHFFFAOYSA-N 0.000 description 1
- HIEHKHQLNIQYRW-UHFFFAOYSA-N tert-butyl 5-[(4-ethoxyphenyl)methyl]-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=CC(OCC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 HIEHKHQLNIQYRW-UHFFFAOYSA-N 0.000 description 1
- USIWCVFUBSIDPU-UHFFFAOYSA-N tert-butyl 5-ethyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(CC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 USIWCVFUBSIDPU-UHFFFAOYSA-N 0.000 description 1
- JLFITVOQNDGSLG-UHFFFAOYSA-N tert-butyl 5-ethylsulfonyl-8-(4-hydroxypiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(O)CC1 JLFITVOQNDGSLG-UHFFFAOYSA-N 0.000 description 1
- BHGFVRXXKCYMQY-UHFFFAOYSA-N tert-butyl 5-ethylsulfonyl-8-[(1-methylimidazol-4-yl)sulfonylamino]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)CC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1NS(=O)(=O)C1=CN(C)C=N1 BHGFVRXXKCYMQY-UHFFFAOYSA-N 0.000 description 1
- WHFMYLOBKXMYGV-UHFFFAOYSA-N tert-butyl 5-ethylsulfonyl-8-nitro-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC([N+]([O-])=O)=CC=C2N(S(=O)(=O)CC)C2=C1CN(C(=O)OC(C)(C)C)CC2 WHFMYLOBKXMYGV-UHFFFAOYSA-N 0.000 description 1
- OOBCGXHTBJONJG-UHFFFAOYSA-N tert-butyl 5-imidazol-1-ylsulfonyl-8-(4-methylpiperidine-1-carbonyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C(=O)OC(C)(C)C)S(=O)(=O)N2C=NC=C2)C3=C1 OOBCGXHTBJONJG-UHFFFAOYSA-N 0.000 description 1
- IYOHKAGDPPKVEL-UHFFFAOYSA-N tert-butyl 8-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-5-ethylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC2=CC=CC=C2CN1C(=O)C(C=C12)=CC=C1N(S(=O)(=O)CC)C1=C2CN(C(=O)OC(C)(C)C)CC1 IYOHKAGDPPKVEL-UHFFFAOYSA-N 0.000 description 1
- CGBISUJBMRBERT-UHFFFAOYSA-N tert-butyl 8-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC2=CC=CC=C2CN1C(=O)C(C=C12)=CC=C1N(S(=O)(=O)CCC)C1=C2CN(C(=O)OC(C)(C)C)CC1 CGBISUJBMRBERT-UHFFFAOYSA-N 0.000 description 1
- RMNZGRPDLWGKKV-UHFFFAOYSA-N tert-butyl 8-(3-methylpiperidine-1-carbonyl)-5-prop-2-enyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1C(C)CCCN1C(=O)C1=CC=C(N(CC=C)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 RMNZGRPDLWGKKV-UHFFFAOYSA-N 0.000 description 1
- PJHXDYOCNFUMRB-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-(4-nitrophenyl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C(=O)OC(C)(C)C)C=2C=CC(=CC=2)[N+]([O-])=O)C3=C1 PJHXDYOCNFUMRB-UHFFFAOYSA-N 0.000 description 1
- CHRIIKXYHLWCPD-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2N=C(C)SC=2)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 CHRIIKXYHLWCPD-UHFFFAOYSA-N 0.000 description 1
- YKLPGWATSHOTHL-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-[(4-methylsulfanylphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=CC(SC)=CC=C1CN1C2=CC=C(C(=O)N3CCC(C)CC3)C=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 YKLPGWATSHOTHL-UHFFFAOYSA-N 0.000 description 1
- GNGDBWSRLMLKRG-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-[(4-methylsulfonylphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(CC=2C=CC(=CC=2)S(C)(=O)=O)C2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 GNGDBWSRLMLKRG-UHFFFAOYSA-N 0.000 description 1
- CZOGQAWGEXGGDD-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-methylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC(C)CCN1C(=O)C1=CC=C(N(C2=C3CN(CC2)C(=O)OC(C)(C)C)S(C)(=O)=O)C3=C1 CZOGQAWGEXGGDD-UHFFFAOYSA-N 0.000 description 1
- BRYCEFNUNAUYGF-UHFFFAOYSA-N tert-butyl 8-(4-methylpiperidine-1-carbonyl)-5-propylsulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C=1C=C2N(S(=O)(=O)CCC)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=1C(=O)N1CCC(C)CC1 BRYCEFNUNAUYGF-UHFFFAOYSA-N 0.000 description 1
- CXLULZJJMIXGDW-UHFFFAOYSA-N tert-butyl 8-(cyclopentanecarbonylamino)-5-methylsulfonyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(N(C2=CC=3)S(C)(=O)=O)C1C2=CC=3NC(=O)C1CCCC1 CXLULZJJMIXGDW-UHFFFAOYSA-N 0.000 description 1
- GDWRVMKCQCPDLX-UHFFFAOYSA-N tert-butyl 8-amino-5-methylsulfonyl-3,4,4a,9b-tetrahydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound NC1=CC=C2N(S(C)(=O)=O)C3CCN(C(=O)OC(C)(C)C)CC3C2=C1 GDWRVMKCQCPDLX-UHFFFAOYSA-N 0.000 description 1
- VTBJNWRKKMETTC-UHFFFAOYSA-N tert-butyl 8-nitro-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound N1C2=CC=C([N+]([O-])=O)C=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 VTBJNWRKKMETTC-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- HQVHOQAKMCMIIM-UHFFFAOYSA-N win 55,212-2 Chemical compound C=12N3C(C)=C(C(=O)C=4C5=CC=CC=C5C=CC=4)C2=CC=CC=1OCC3CN1CCOCC1 HQVHOQAKMCMIIM-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500654 | 2005-03-22 | ||
| PCT/SE2006/000339 WO2006101434A1 (en) | 2005-03-22 | 2006-03-17 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534496A true JP2008534496A (ja) | 2008-08-28 |
| JP2008534496A5 JP2008534496A5 (enExample) | 2009-04-23 |
Family
ID=37024033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502944A Abandoned JP2008534496A (ja) | 2005-03-22 | 2006-03-17 | CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100113502A1 (enExample) |
| EP (1) | EP1863810A4 (enExample) |
| JP (1) | JP2008534496A (enExample) |
| CN (2) | CN101175754A (enExample) |
| AR (1) | AR053699A1 (enExample) |
| TW (1) | TW200716628A (enExample) |
| UY (1) | UY29427A1 (enExample) |
| WO (1) | WO2006101434A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011510932A (ja) * | 2008-01-25 | 2011-04-07 | メディベイション テクノロジーズ, インコーポレイテッド | 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法 |
| JP2014101389A (ja) * | 2008-01-25 | 2014-06-05 | Medivation Technologies Inc | 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1937263A2 (en) * | 2005-10-04 | 2008-07-02 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| EA014906B1 (ru) * | 2005-12-01 | 2011-02-28 | Элан Фармасьютикалз, Инк. | 5-(арилсульфонил)пиразолопиперидины |
| WO2008036021A1 (en) * | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands |
| WO2008036022A1 (en) * | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands |
| RU2329044C1 (ru) * | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| US20090062251A1 (en) * | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| CN101868234A (zh) | 2007-09-20 | 2010-10-20 | D2E有限公司 | 具有神经保护和认知增强特性的氢化吡啶并[4,3-b]吲哚的含氟衍生物,其制备方法及应用 |
| ES2552733T3 (es) | 2007-11-16 | 2015-12-01 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| US8129390B2 (en) | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
| TWI498328B (zh) * | 2008-01-25 | 2015-09-01 | Medivation Technologies Inc | 新穎之2,3,4,5-四氫-1h-吡啶并〔4,3-b〕吲哚化合物及其使用方法 |
| BRPI0911681B8 (pt) | 2008-04-23 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro |
| CN102271508B (zh) | 2008-10-31 | 2015-04-29 | 梅迪维新技术公司 | 含有刚性部分的吡啶并[4,3-b]吲哚类化合物 |
| CA2742322A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino[4,5-b]indoles and methods of use |
| US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
| CN102153549B (zh) * | 2010-12-14 | 2012-11-14 | 华东理工大学 | γ咔啉化合物、制备方法和用途 |
| AU2012207335A1 (en) | 2011-01-19 | 2013-07-25 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| AU2012219251B2 (en) | 2011-02-18 | 2016-05-12 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| CN103864779B (zh) * | 2012-12-07 | 2016-06-22 | 天津科技大学 | 一种1-(苯基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚衍生物的制备及其在抗肿瘤药物中的应用 |
| CN103864781A (zh) * | 2012-12-13 | 2014-06-18 | 天津科技大学 | 一种新型1,9-二取代四氢咔啉类衍生物的制备及其抗肿瘤药物中的应用 |
| BR112015029455A8 (pt) * | 2013-05-28 | 2020-03-17 | Astrazeneca Ab | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer |
| DK3433256T3 (da) | 2016-10-24 | 2019-10-28 | Astrazeneca | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolinderivat, der er anvendeligt til behandling af cancer |
| ES2766249T3 (es) | 2017-01-30 | 2020-06-12 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| KR20230005270A (ko) | 2020-04-24 | 2023-01-09 | 아스트라제네카 아베 | 약학적 제형 |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| CN116425670A (zh) * | 2022-07-15 | 2023-07-14 | 英矽智能科技(上海)有限公司 | 作为tead抑制剂的新型杂环化合物 |
| KR20240141133A (ko) * | 2023-03-15 | 2024-09-25 | 한국과학기술연구원 | 신규한 피리도인돌 유도체 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US62251A (en) * | 1867-02-19 | Improvement in machines foe burnishing plated ware | ||
| JPH0256485A (ja) * | 1988-04-27 | 1990-02-26 | Glaxo Group Ltd | ラクタム誘導体 |
| US5008272A (en) * | 1988-08-15 | 1991-04-16 | Glaxo Group Limited | Lactam derivatives |
| US6448257B1 (en) * | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| EP1254115A2 (en) * | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| CO5300399A1 (es) * | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| US7534897B2 (en) * | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| JP2005162657A (ja) * | 2003-12-02 | 2005-06-23 | Takeda Chem Ind Ltd | カンナビノイド受容体調節剤 |
| WO2008036022A1 (en) * | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands |
| WO2008036021A1 (en) * | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands |
-
2006
- 2006-03-17 JP JP2008502944A patent/JP2008534496A/ja not_active Abandoned
- 2006-03-17 US US11/909,089 patent/US20100113502A1/en not_active Abandoned
- 2006-03-17 EP EP06717024A patent/EP1863810A4/en not_active Withdrawn
- 2006-03-17 WO PCT/SE2006/000339 patent/WO2006101434A1/en not_active Ceased
- 2006-03-17 TW TW095109101A patent/TW200716628A/zh unknown
- 2006-03-17 CN CNA2006800168097A patent/CN101175754A/zh active Pending
- 2006-03-17 CN CN2010105223008A patent/CN102030750A/zh active Pending
- 2006-03-20 UY UY29427A patent/UY29427A1/es not_active Application Discontinuation
- 2006-03-22 AR ARP060101132A patent/AR053699A1/es unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011510932A (ja) * | 2008-01-25 | 2011-04-07 | メディベイション テクノロジーズ, インコーポレイテッド | 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法 |
| JP2014101389A (ja) * | 2008-01-25 | 2014-06-05 | Medivation Technologies Inc | 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法 |
| US9115137B2 (en) | 2008-01-25 | 2015-08-25 | Medivation Technologies, Inc. | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101175754A (zh) | 2008-05-07 |
| AR053699A1 (es) | 2007-05-16 |
| WO2006101434A1 (en) | 2006-09-28 |
| EP1863810A4 (en) | 2010-03-31 |
| TW200716628A (en) | 2007-05-01 |
| CN102030750A (zh) | 2011-04-27 |
| UY29427A1 (es) | 2006-10-31 |
| EP1863810A1 (en) | 2007-12-12 |
| US20100113502A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534496A (ja) | CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 | |
| EP2953940B1 (en) | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists | |
| US20090062251A1 (en) | Novel Compounds 002 | |
| AU2007244002A1 (en) | Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, Alzheimer's disease and/or Schizophrenia | |
| CN117616030A (zh) | 食欲素受体激动剂及其用途 | |
| JP6173431B2 (ja) | モルヒナン誘導体 | |
| SA07280303B1 (ar) | مشتقات بها استبدال من (3as, 7as)-1-3A,4,5,6,7-Hexahydro-3H-Benzoimidazol-2-One والعمليات الخاصة بتحضيرها، والتركيبات المحتوية عليها والتطبيقات | |
| CN114828963A (zh) | 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物 | |
| WO2008100621A2 (en) | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s | |
| WO2008100618A2 (en) | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
| AU2012323038B2 (en) | 2-oxo-piperidinyl derivatives | |
| WO2020085234A1 (ja) | モルヒナン誘導体 | |
| WO2008036021A1 (en) | Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands | |
| JP2023545065A (ja) | オートタキシン抑制剤化合物 | |
| AU2005287429A1 (en) | Compounds, compositions containing them, preparations thereof and uses thereof II | |
| EP4543446A1 (en) | Substituted fused bicyclic compounds and related methods of treatment | |
| JP7678756B2 (ja) | アゼパン誘導体 | |
| JP2013523806A (ja) | スルタム化合物 | |
| JP2023015414A (ja) | エポキシアゼパン誘導体 | |
| WO2008036022A1 (en) | Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands | |
| JP2013518094A (ja) | γ−セクレターゼモジュレーターとしてのアミノシクロヘキサンおよびアミノテトラヒドロピランならびに関連化合物 | |
| MXPA06008941A (en) | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | |
| KR20070057856A (ko) | 화합물, 그를 함유하는 조성물, 그의 제조 방법 및 그의용도 | |
| MX2007003121A (es) | Derivados de bencimidazol, compuestos, composiciones que los contienen, preparacion y usos de los mismos ii. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090303 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090303 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20090424 |